Related references
Note: Only part of the references are listed.Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data
Philip Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-Naive Patients With Moderately-to-Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Multicenter, Multi-Country, Randomized, Double-Blind, Active Comparator-Controlled Trial
Ronald van Vollenhoven et al.
ARTHRITIS & RHEUMATOLOGY (2020)
Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment
Josef S. Smolen et al.
JOURNAL OF RHEUMATOLOGY (2019)
Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis
Masayoshi Harigai
RHEUMATOLOGY (2019)
Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study
Josef S. Smolen et al.
LANCET (2019)
A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis
Katie Bechman et al.
RHEUMATOLOGY (2019)
Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response
Roy M. Fleischmann et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial
Mark C. Genovese et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Cardiovascular safety of tocilizumab: A systematic review and network meta-analysis
Benjamin Castagne et al.
PLOS ONE (2019)
Small-Molecule Protein Kinases Inhibitors and the Risk of Fungal Infections
Katie Bechman et al.
CURRENT FUNGAL INFECTION REPORTS (2019)
Managing varicella zoster virus contact and infection in patients on anti-rheumatic therapy
Matthew Cates et al.
RHEUMATOLOGY (2018)
Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older
Anthony L. Cunningham et al.
JOURNAL OF INFECTIOUS DISEASES (2018)
Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial
Mark C. Genovese et al.
LANCET (2018)
Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial
Gerd R. Burmester et al.
LANCET (2018)
Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)
A. Kavanaugh et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)
R. Westhovens et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs
A. Strangfeld et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
The emerging safety profile of JAK inhibitors in rheumatic disease
Kevin L. Winthrop
NATURE REVIEWS RHEUMATOLOGY (2017)
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials
Stanley B. Cohen et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis: a meta-analysis
Bethany T. Samuelson et al.
BLOOD COAGULATION & FIBRINOLYSIS (2016)
Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older
A. L. Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies
Juergen Wollenhaupt et al.
JOURNAL OF RHEUMATOLOGY (2014)
Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies
M Abu-Shakra et al.
ANNALS OF THE RHEUMATIC DISEASES (2001)